Rising Cancer Cases Propel Antineoplastic Agent Market Growth Driving Market Acceleration in the Anti-Neoplastic Agents Industry, 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Anti-Neoplastic Agents Market Size By 2025?
In recent times, there has been significant growth in the anti-neoplastic agents market. The size of this market is expected to increase from $130.01 billion in 2024 to $142.82 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.9%. Factors contributing to this growth in the historic period include the rise in cancer cases, increased demand for therapies, growing preference for minimally invasive cancer treatments, and a surge in demand for cost-effective anti-neoplastic treatments.

How Big Is the Anti-Neoplastic Agents Market Size Expected to Grow by 2029?
Expectations are high for robust expansion in the anti-neoplastic agents market in the coming years. The market is projected to reach $202.12 billion by 2029, increasing at a compound annual growth rate (CAGR) of 9.1%. The anticipated growth during the forecast period is linked to factors such as increased patient knowledge and awareness, government interventions, rising demand for customizable cancer therapies, and an intensified focus on life quality during cancer treatment. Key trends likely to be seen in this period include progress in oncology research, development of targeted therapies, breakthroughs in biotechnology, and improvements in diagnostic tools.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report

Which Key Market Drivers Powering Anti-Neoplastic Agents Market Expansion and Growth?
The escalating prevalence of cancer globally is anticipated to stimulate growth in the market for antineoplastic agents. Cancer refers to a collective group of diseases that can occur anywhere in the body when rogue cells grow without control, break their normal constraints, and either expand to other organs or invade adjacent body parts. Antineoplastic agents are crucial in cancer therapy as they impede cancer cell proliferation and division through various means, such as causing DNA damage, disrupting the cell cycle, and interfering with vital cellular pathways. For example, the International Agency for Research on Cancer (IARC), a France-based global agency that fosters shared efforts in cancer research, proclaimed in February 2024 that by 2050, the cancer burden is predicted to rise to over 35 million, a hike of 77% from the estimated 20 million in 2022. Therefore, the growing incidences of cancer are propelling the antineoplastic agent market forward. A critical driving factor for the anti-neoplastic agents market is the increasing investment in cancer research. Financial backing extended to research endeavours focused on studying, preventing, diagnosing, and treating cancer is what constitutes investment in cancer research. Enhanced funding in this area enables pharmaceutical and biotech companies to engage in the identification, development, and thorough testing of new antineoplastic agents, which includes discerning drug targets and formulating potential candidates. For example, in March 2022, the Department of Health and Aged Care, a government agency in Australia, committed $893.5 million to bolster cancer services and results. This funding includes $329.4 million for novel cancer drugs like Trodelvy for triple-negative breast cancer, Lynparza for metastatic castration-resistant prostate cancer, and Mylotarg for acute myeloid leukemia, which could help hundreds of patients every year. Thus, increasing investment in cancer research is set to boost growth in the anti-neoplastic agent market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Anti-Neoplastic Agents Market?
Leading businesses in the anti-neoplastic agent market are aiming to establish sustainable clinical practices. For example, Novartis AG, a pharmaceutical organization based in Switzerland, obtained approval from the Food and Drug Administration (FDA) in March 2022 for the use of Pluvicto, which is a first targeted radioligand therapy for the treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer (mCRPC). It is advised to administer 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks, up to a maximum of six doses or until the disease progresses or unbearable toxicity is experienced, whichever arrives first. Patients with mCRPC, previously treated, should be selected for treatment with Pluvicto based on PSMA expression in tumors and should be identified using Locametz or another authorized PSMA-11 imaging agent.

What Are the Emerging Segments in the Anti-Neoplastic Agents Market?
The anti-neoplastic agents market covered in this report is segmented -

1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous
2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers

Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists
3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids
4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12901&type=smp

Who Are the Global Leaders in the Anti-Neoplastic Agents Market?
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.

Which are the Top Profitable Regional Markets for the Anti-Neoplastic Agents Industry?
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.